Karen Chung of Chester Springs has received one of the nation’s first treatments for early symptomatic Alzheimer’s disease, ...

Eli Lilly & Co. Inc. said Tuesday the Japanese regulator has approved its Kisunla treatment for adults with early symptomatic ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

The Ministry of Health, Labour and Welfare Japan has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks ...

Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive ...

Eli Lilly on Tuesday said Japan's Ministry of Health, Labour and Welfare Japan approved Kisunla for adults with early symptomatic Alzheimer's, including those with mild cognitive impairment as well as ...

The 829 registered participants from 156 teams in Sunday's Walk to End Alzheimer's Northern Virginia, held at Reston Town ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

"Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease by significantly slowing cognitive and functional decline in our TRAILBLAZER-ALZ 2 study ...

The excessive buildup of amyloid plaques in the brain may lead to memory and thinking issues associated with Alzheimer's disease.4,5 Kisunla can help the body remove the excessive buildup of ...